O	0	3	Bcl	Bcl	NN	B-NP
O	3	4	-	-	HYPH	O
O	4	5	2	2	CD	B-NP
O	6	15	decreases	decrease	VBZ	B-VP
B-Cell	16	20	cell	cell	NN	B-NP
O	21	34	proliferation	proliferation	NN	I-NP
O	35	38	and	and	CC	O
O	39	47	promotes	promote	VBZ	B-VP
O	48	60	accumulation	accumulation	NN	B-NP
O	61	63	of	of	IN	B-PP
B-Cell	64	69	cells	cell	NNS	B-NP
O	70	72	in	in	IN	B-PP
O	73	74	S	S	NN	B-NP
O	75	80	phase	phase	NN	I-NP
O	81	88	without	without	IN	B-PP
O	89	98	affecting	affect	VBG	B-VP
O	99	102	the	the	DT	B-NP
O	103	107	rate	rate	NN	I-NP
O	108	110	of	of	IN	B-PP
O	111	120	apoptosis	apoptosis	NN	B-NP
O	121	123	in	in	IN	B-PP
O	124	129	human	human	JJ	B-NP
B-Cell	130	137	ovarian	ovarian	JJ	I-NP
I-Cell	138	147	carcinoma	carcinoma	NN	I-NP
I-Cell	148	153	cells	cell	NNS	I-NP
O	153	154	.	.	.	O

O	155	165	OBJECTIVES	OBJECTIVES	NNS	B-NP
O	165	166	:	:	:	O

O	167	170	The	The	DT	B-NP
O	171	174	Bcl	Bcl	NN	I-NP
O	174	175	-	-	HYPH	I-NP
O	175	176	2	2	CD	I-NP
O	177	184	protein	protein	NN	I-NP
O	185	187	is	be	VBZ	B-VP
O	188	190	an	an	DT	B-NP
O	191	200	important	important	JJ	I-NP
O	201	210	regulator	regulator	NN	I-NP
O	211	213	of	of	IN	B-PP
O	214	217	the	the	DT	B-NP
O	218	227	apoptotic	apoptotic	JJ	I-NP
O	228	235	cascade	cascade	NN	I-NP
O	236	239	and	and	CC	O
O	240	248	promotes	promote	VBZ	B-VP
B-Cell	249	253	cell	cell	NN	B-NP
O	254	262	survival	survival	NN	I-NP
O	262	263	.	.	.	O

O	264	267	Bcl	Bcl	NN	B-NP
O	267	268	-	-	HYPH	B-NP
O	268	269	2	2	CD	I-NP
O	270	273	can	can	MD	B-VP
O	274	278	also	also	RB	I-VP
O	279	284	delay	delay	VB	I-VP
O	285	290	entry	entry	NN	B-NP
O	291	295	into	into	IN	B-PP
O	296	299	the	the	DT	B-NP
B-Cell	300	304	cell	cell	NN	I-NP
O	305	310	cycle	cycle	NN	I-NP
O	311	315	from	from	IN	B-PP
O	316	326	quiescence	quiescence	NN	B-NP
O	326	327	.	.	.	O

O	328	330	In	In	IN	B-PP
O	331	334	the	the	DT	B-NP
O	335	342	present	present	JJ	I-NP
O	343	348	study	study	NN	I-NP
O	348	349	,	,	,	O
O	350	352	we	we	PRP	B-NP
O	353	357	used	use	VBD	B-VP
O	358	361	two	two	CD	B-NP
O	362	370	isogenic	isogenic	JJ	I-NP
O	371	376	human	human	JJ	I-NP
B-Cell	377	384	ovarian	ovarian	JJ	I-NP
I-Cell	385	394	carcinoma	carcinoma	NN	I-NP
I-Cell	395	399	cell	cell	NN	I-NP
I-Cell	400	405	lines	line	NNS	I-NP
O	405	406	,	,	,	O
O	407	412	which	which	WDT	B-NP
O	413	422	expressed	express	VBD	B-VP
O	423	435	differential	differential	JJ	B-NP
O	436	442	levels	level	NNS	I-NP
O	443	445	of	of	IN	B-PP
O	446	449	Bcl	Bcl	NN	B-NP
O	449	450	-	-	HYPH	B-NP
O	450	451	2	2	CD	I-NP
O	452	460	proteins	protein	NNS	I-NP
O	460	461	,	,	,	O
O	462	464	to	to	TO	B-VP
O	465	476	demonstrate	demonstrate	VB	I-VP
O	477	481	that	that	IN	B-SBAR
O	482	485	Bcl	Bcl	NN	B-NP
O	485	486	-	-	HYPH	O
O	486	487	2	2	CD	B-NP
O	488	491	may	may	MD	B-VP
O	492	500	regulate	regulate	VB	I-VP
O	501	504	the	the	DT	B-NP
O	505	511	growth	growth	NN	I-NP
O	512	517	rates	rate	NNS	I-NP
O	518	520	of	of	IN	B-PP
B-Cell	521	535	adenocarcinoma	adenocarcinoma	NN	B-NP
I-Cell	536	541	cells	cell	NNS	I-NP
O	541	542	.	.	.	O

O	543	550	METHODS	METHODS	NNS	B-NP
O	550	551	:	:	:	O

O	552	555	The	The	DT	B-NP
O	556	562	growth	growth	NN	I-NP
O	563	568	rates	rate	NNS	I-NP
O	569	571	of	of	IN	B-PP
O	572	575	two	two	CD	B-NP
O	576	584	isogenic	isogenic	JJ	I-NP
B-Cell	585	592	ovarian	ovarian	JJ	I-NP
I-Cell	593	599	cancer	cancer	NN	I-NP
I-Cell	600	604	cell	cell	NN	I-NP
I-Cell	605	610	lines	line	NNS	I-NP
O	611	615	were	be	VBD	B-VP
O	616	626	determined	determine	VBN	I-VP
O	627	629	by	by	IN	B-PP
O	630	633	XTT	XTT	NN	B-NP
O	634	640	assays	assay	NNS	I-NP
O	641	644	and	and	CC	O
O	645	649	flow	flow	NN	B-NP
O	650	659	cytometry	cytometry	NN	I-NP
O	660	668	combined	combine	VBN	B-VP
O	669	673	with	with	IN	B-PP
O	674	676	PI	PI	NN	B-NP
O	677	685	staining	staining	NN	I-NP
O	685	686	.	.	.	O

B-Cell	687	690	Bcl	Bcl	NN	B-NP
I-Cell	690	691	-	-	HYPH	B-NP
I-Cell	691	692	2	2	CD	I-NP
I-Cell	692	693	-	-	HYPH	I-NP
I-Cell	693	707	overexpressing	overexpresse	VBG	I-NP
I-Cell	708	713	SKOV3	SKOV3	NN	I-NP
I-Cell	714	719	cells	cell	NNS	I-NP
O	720	724	were	be	VBD	B-VP
O	725	733	modified	modify	VBN	I-VP
O	734	736	to	to	TO	I-VP
O	737	744	express	express	VB	I-VP
O	745	746	a	a	DT	B-NP
O	747	758	doxycycline	doxycycline	NN	I-NP
O	758	759	-	-	HYPH	O
O	759	768	inducible	inducible	JJ	B-NP
O	769	773	anti	anti	AFX	I-NP
O	773	774	-	-	HYPH	I-NP
O	774	777	Bcl	Bcl	NN	I-NP
O	777	778	-	-	HYPH	I-NP
O	778	779	2	2	CD	I-NP
O	780	786	single	single	JJ	I-NP
O	786	787	-	-	HYPH	I-NP
O	787	792	chain	chain	NN	I-NP
O	793	801	antibody	antibody	NN	I-NP
O	802	805	and	and	CC	O
O	806	809	the	the	DT	B-NP
O	810	817	effects	effect	NNS	I-NP
O	818	820	of	of	IN	B-PP
O	821	824	Bcl	Bcl	NN	B-NP
O	824	825	-	-	HYPH	B-NP
O	825	826	2	2	CD	I-NP
O	827	834	protein	protein	NN	I-NP
O	835	845	inhibition	inhibition	NN	I-NP
O	846	848	on	on	IN	B-PP
B-Cell	849	853	cell	cell	NN	B-NP
O	854	867	proliferation	proliferation	NN	I-NP
O	868	871	and	and	CC	I-NP
O	872	881	apoptosis	apoptosis	NN	I-NP
O	882	886	were	be	VBD	B-VP
O	887	895	assessed	assess	VBN	I-VP
O	895	896	.	.	.	O

O	897	904	RESULTS	RESULTS	NNS	B-NP
O	904	905	:	:	:	O

O	906	908	We	We	PRP	B-NP
O	909	920	demonstrate	demonstrate	VBP	B-VP
O	921	925	that	that	IN	B-SBAR
O	926	929	Bcl	Bcl	NN	B-NP
O	929	930	-	-	HYPH	B-NP
O	930	931	2	2	CD	I-NP
O	932	940	promotes	promote	VBZ	B-VP
O	941	944	the	the	DT	B-NP
O	945	957	accumulation	accumulation	NN	I-NP
O	958	960	of	of	IN	B-PP
O	961	974	proliferating	proliferate	VBG	B-VP
B-Cell	975	984	carcinoma	carcinoma	NN	B-NP
I-Cell	985	990	cells	cell	NNS	I-NP
O	991	993	in	in	IN	B-PP
O	994	995	S	S	NN	B-NP
O	996	1001	phase	phase	NN	I-NP
O	1001	1002	.	.	.	O

O	1003	1006	The	The	DT	B-NP
B-Cell	1007	1010	Bcl	Bcl	NN	I-NP
I-Cell	1010	1011	-	-	HYPH	B-NP
I-Cell	1011	1012	2	2	CD	I-NP
I-Cell	1012	1013	-	-	HYPH	I-NP
I-Cell	1013	1027	overexpressing	overexpresse	VBG	I-NP
I-Cell	1028	1033	SKOV3	SKOV3	NN	I-NP
I-Cell	1034	1038	cell	cell	NN	I-NP
I-Cell	1039	1043	line	line	NN	I-NP
O	1044	1056	proliferates	proliferate	VBZ	B-VP
O	1057	1065	markedly	markedly	RB	B-ADJP
O	1066	1072	faster	fast	JJR	I-ADJP
O	1073	1076	and	and	CC	O
O	1077	1082	shows	show	VBZ	B-VP
O	1083	1090	delayed	delay	VBN	B-NP
O	1091	1102	progression	progression	NN	I-NP
O	1103	1105	to	to	TO	B-PP
O	1106	1109	G2M	G2M	NN	B-NP
O	1110	1115	phase	phase	NN	I-NP
O	1116	1124	compared	compare	VBN	B-VP
O	1125	1127	to	to	TO	B-PP
O	1128	1131	its	its	PRP$	B-NP
O	1132	1135	low	low	JJ	I-NP
B-Cell	1136	1139	Bcl	Bcl	NN	I-NP
I-Cell	1139	1140	-	-	HYPH	B-NP
I-Cell	1140	1141	2	2	CD	I-NP
I-Cell	1141	1142	-	-	HYPH	I-NP
I-Cell	1142	1152	expressing	express	VBG	I-NP
I-Cell	1153	1164	counterpart	counterpart	NN	I-NP
I-Cell	1165	1170	SKOV3	SKOV3	NN	I-NP
I-Cell	1170	1171	.	.	.	O
I-Cell	1171	1174	ip1	ip1	NN	B-NP
I-Cell	1175	1179	cell	cell	NN	I-NP
I-Cell	1180	1184	line	line	NN	I-NP
O	1184	1185	.	.	.	O

O	1186	1192	Single	Single	JJ	B-NP
O	1192	1193	-	-	HYPH	I-NP
O	1193	1198	chain	chain	NN	I-NP
O	1199	1207	antibody	antibody	NN	I-NP
O	1207	1208	-	-	HYPH	B-VP
O	1208	1216	mediated	mediate	VBN	B-NP
O	1217	1227	inhibition	inhibition	NN	I-NP
O	1228	1230	of	of	IN	B-PP
O	1231	1234	Bcl	Bcl	NN	B-NP
O	1234	1235	-	-	HYPH	B-NP
O	1235	1236	2	2	CD	I-NP
O	1237	1239	in	in	IN	B-PP
B-Cell	1240	1245	SKOV3	SKOV3	NN	B-NP
I-Cell	1246	1251	cells	cell	NNS	I-NP
O	1252	1255	was	be	VBD	B-VP
O	1256	1266	associated	associate	VBN	I-VP
O	1267	1271	with	with	IN	B-PP
O	1272	1281	increased	increase	VBN	B-NP
O	1282	1288	growth	growth	NN	I-NP
O	1289	1294	rates	rate	NNS	I-NP
O	1295	1298	and	and	CC	O
O	1299	1303	more	more	RBR	B-NP
O	1304	1309	rapid	rapid	JJ	I-NP
B-Cell	1310	1314	cell	cell	NN	I-NP
O	1315	1320	cycle	cycle	NN	I-NP
O	1321	1332	progression	progression	NN	I-NP
O	1332	1333	.	.	.	O

O	1334	1343	Treatment	Treatment	NN	B-NP
O	1344	1348	with	with	IN	B-PP
O	1349	1358	cisplatin	cisplatin	NN	B-NP
O	1359	1367	resulted	result	VBD	B-VP
O	1368	1370	in	in	IN	B-PP
O	1371	1375	more	more	JJR	B-NP
B-Cell	1376	1381	cells	cell	NNS	I-NP
O	1382	1394	accumulating	accumulate	VBG	B-VP
O	1395	1397	in	in	IN	B-PP
O	1398	1399	S	S	NN	B-NP
O	1400	1405	phase	phase	NN	I-NP
O	1406	1408	in	in	IN	B-PP
B-Cell	1409	1412	Bcl	Bcl	NN	B-NP
I-Cell	1412	1413	-	-	HYPH	B-NP
I-Cell	1413	1414	2	2	CD	I-NP
I-Cell	1414	1415	-	-	HYPH	I-NP
I-Cell	1415	1429	overexpressing	overexpresse	VBG	I-NP
I-Cell	1430	1435	SKOV3	SKOV3	NN	I-NP
I-Cell	1436	1441	cells	cell	NNS	I-NP
O	1441	1442	,	,	,	O
O	1443	1448	while	while	IN	B-SBAR
O	1449	1452	the	the	DT	B-NP
O	1453	1463	inhibition	inhibition	NN	I-NP
O	1464	1466	of	of	IN	B-PP
O	1467	1470	Bcl	Bcl	NN	B-NP
O	1470	1471	-	-	HYPH	B-NP
O	1471	1472	2	2	CD	I-NP
O	1473	1482	abolished	abolish	VBD	B-VP
O	1483	1490	delayed	delay	VBN	B-NP
O	1491	1496	entry	entry	NN	I-NP
O	1497	1501	into	into	IN	B-PP
O	1502	1505	G2M	G2M	NN	B-NP
O	1506	1511	phase	phase	NN	I-NP
O	1512	1519	without	without	IN	B-PP
O	1520	1529	affecting	affect	VBG	B-VP
O	1530	1539	cisplatin	cisplatin	NN	B-NP
O	1539	1540	-	-	HYPH	B-NP
O	1540	1547	induced	induce	VBN	I-NP
O	1548	1557	apoptosis	apoptosis	NN	I-NP
O	1557	1558	.	.	.	O

O	1559	1570	CONCLUSIONS	CONCLUSIONS	NNS	B-NP
O	1570	1571	:	:	:	O

O	1572	1575	Our	Our	PRP$	B-NP
O	1576	1583	results	result	NNS	I-NP
O	1584	1591	suggest	suggest	VBP	B-VP
O	1592	1596	that	that	IN	B-SBAR
O	1596	1597	,	,	,	O
O	1598	1600	in	in	IN	B-PP
B-Cell	1601	1608	ovarian	ovarian	JJ	B-NP
I-Cell	1609	1615	cancer	cancer	NN	I-NP
I-Cell	1616	1621	cells	cell	NNS	I-NP
O	1621	1622	,	,	,	O
O	1623	1626	Bcl	Bcl	NN	B-NP
O	1626	1627	-	-	HYPH	B-NP
O	1627	1628	2	2	CD	I-NP
O	1629	1635	delays	delay	NNS	I-NP
B-Cell	1636	1640	cell	cell	NN	I-NP
O	1641	1646	cycle	cycle	NN	I-NP
O	1647	1658	progression	progression	NN	I-NP
O	1659	1661	by	by	IN	B-PP
O	1662	1671	promoting	promote	VBG	B-VP
O	1672	1684	accumulation	accumulation	NN	B-NP
O	1685	1687	of	of	IN	B-PP
B-Cell	1688	1693	cells	cell	NNS	B-NP
O	1694	1696	in	in	IN	B-PP
O	1697	1698	S	S	NN	B-NP
O	1699	1704	phase	phase	NN	I-NP
O	1705	1712	without	without	IN	B-PP
O	1713	1722	affecting	affect	VBG	B-VP
O	1723	1726	the	the	DT	B-NP
O	1727	1731	rate	rate	NN	I-NP
O	1732	1734	of	of	IN	B-PP
O	1735	1744	apoptosis	apoptosis	NN	B-NP
O	1744	1745	.	.	.	O

O	1746	1750	Thus	Thus	RB	B-ADVP
O	1750	1751	,	,	,	O
O	1752	1754	in	in	IN	B-PP
O	1755	1763	addition	addition	NN	B-NP
O	1764	1766	to	to	TO	B-PP
O	1767	1770	its	its	PRP$	B-NP
O	1771	1776	known	known	JJ	I-NP
O	1777	1781	role	role	NN	I-NP
O	1782	1784	at	at	IN	B-PP
O	1785	1788	the	the	DT	B-NP
O	1789	1791	G0	G0	NN	I-NP
O	1791	1792	/	/	SYM	B-NP
O	1792	1794	G1	G1	NN	I-NP
O	1795	1805	checkpoint	checkpoint	NN	I-NP
O	1805	1806	,	,	,	O
O	1807	1809	we	we	PRP	B-NP
O	1810	1821	demonstrate	demonstrate	VBP	B-VP
O	1822	1825	for	for	IN	B-PP
O	1826	1829	the	the	DT	B-NP
O	1830	1835	first	first	JJ	I-NP
O	1836	1840	time	time	NN	I-NP
O	1841	1845	that	that	IN	B-ADVP
O	1846	1849	Bcl	Bcl	NN	B-NP
O	1849	1850	-	-	HYPH	O
O	1850	1851	2	2	CD	B-NP
O	1852	1856	also	also	RB	B-ADVP
O	1857	1866	regulates	regulate	VBZ	B-VP
O	1867	1870	the	the	DT	B-NP
O	1871	1872	S	S	NN	I-NP
O	1873	1878	phase	phase	NN	I-NP
O	1878	1879	.	.	.	O

